Tag
Acmopatide, a novel biased GLP-1/GIP receptor agonist, improves glycemic control and reduces body weight without severe adverse events in overweight adults with type 1 diabetes, based on a 16-week phase 2 randomized trial.
This review synthesizes current evidence on low-carbohydrate diets in gestational diabetes mellitus (GDM), highlighting effects on glycemia, nutrient adequacy, and perinatal outcomes from the DiGest trial and supporting literature.
The DASH4D diet, a diabetes-adapted version of the DASH eating plan, significantly improves blood pressure and blood sugar control in type 2 diabetes with hypertension, offering a strong evidence-based dietary recommendation for personalize
The CONNECT trial demonstrates that continuous glucose monitoring (CGM) significantly improves glycemic control in adults with non-insulin-treated type 2 diabetes managed in primary care, reducing HbA1c levels and hyperglycemia risk without
The twiist AID system significantly improves glycemic control and patient satisfaction in insulin-treated type 2 diabetes over 13 weeks, demonstrating safety and effectiveness supported by complementary real-world and RCT data.
Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, significantly reduces bodyweight and improves glycemic control in adults with obesity and type 2 diabetes, showing promising efficacy and a manageable safety profil
Continuous glucose monitoring-guided insulin optimization improves glycemic control and nutritional status in insulin-treated adults receiving long-term nocturnal parenteral nutrition, reducing hyperglycemia and associated complications.
This study explores how the choice of diabetes self-care location at school affects glycemic control in children with Type 1 diabetes, highlighting restroom use as a risk factor for poorer outcomes and emphasizing the need for supportive sc
Updated meta-analysis reveals modest HbA1C improvements with behavioral interventions in youth with type 1 diabetes, highlighting the superiority of family-focused, multicomponent approaches over single-focus programs.
This study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualize
The DASH4D diet, a tailored DASH-style intervention for diabetes, significantly improved key glycemic biomarkers including fructosamine, fasting glucose, and HbA1c compared to a typical American diet in adults with type 2 diabetes.
A phase 3 trial demonstrated that HTD1801 monotherapy significantly reduces HbA1c and improves cardiometabolic and inflammatory markers in patients with inadequately controlled type 2 diabetes, with sustained effects and a favorable safety
This review synthesizes evidence on daily and weekly patterns of glycemic control in real-world CGM data, highlighting small but consistent temporal variations that inform personalized diabetes care.
A 6-month randomized controlled trial found that time-restricted eating (TRE) in adults with type 1 diabetes is safe and improves HbA1c levels but does not significantly reduce body weight compared to calorie restriction or no intervention.
This study highlights that higher baseline and maintained C-peptide levels in type 1 diabetes are linked to reduced risks of acute complications and retinopathy, underscoring the importance of preserving endogenous insulin secretion.
The ENDO trial demonstrates that the EndoBarrier duodenal-jejunal bypass liner significantly improves glycemic control and induces meaningful weight loss in patients with poorly controlled type 2 diabetes and obesity, with an acceptable saf
A 12-week randomized trial explored sleep optimization in adults with type 1 diabetes, revealing improved sleep quality and reduced diabetes distress but limited glycemic benefits except in patients with baseline A1C ≥7%.
This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in thos
Surgical therapy for diabetic gastroparesis was linked to better long-term HbA1c control, less insulin use, and fewer diabetes-related complications, though mortality was unchanged.
The FreeDM2 trial demonstrates that real-time CGM significantly improves HbA1c levels compared to SMBG in adults with type 2 diabetes on basal insulin and modern therapies, with sustained benefits over 32 weeks.
